SII becomes India’s first vaccine to seek government nod for emergency use

The Serum Institute of India became the first indigineous company to seek emergency use authorisation for Oxford COVID-19 vaccine use in the country.

This comes after the Indian arm of U.S. pharmaceutical giant Pfizer yesterday sought approval from India’s drug regulator for its COVID-19 vaccine in the country, after securing such clearance in the UK and Bahrain.

As of now the phase-3 clinical trial of Oxford COVID-19 vaccine, Covidshield is being conducted by the Pune based Serium Institute and Indian Council of Medical Research in various parts of country.

According to ICMR, the Serum Institute of Indian has already manufactured 40 million doses of vaccine under the stockpiling license obtained from Drugs Controller General of India.